AI-Generated Peptide Targets Rare Blood Disorder in New Research
A paper in Blood Advances describes an AI-designed peptide for platelet-type von Willebrand disease, adding to the growing evidence that AI is accelerating drug discovery for rare conditions.
A paper published in Blood Advances describes the development of an artificial intelligence-generated peptide targeting platelet-type von Willebrand disease, a rare bleeding disorder, as highlighted by @BloodPortfolio. Rare diseases are a natural fit for AI-driven drug discovery because the traditional pharmaceutical economics — large patient populations justifying large R&D budgets — don't apply. AI can dramatically reduce the cost of candidate identification and optimization.
Unlock the full briefing
Get every story in today's briefing, the full archive, and the daily AI intelligence brief.
All stories today
Full archive
Daily brief
Cancel anytime. Payments powered by Stripe.